Patents by Inventor Norton P. Peet

Norton P. Peet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of viral entry into mammalian cells
    Patent number: 9212134
    Abstract: The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: December 15, 2015
    Assignee: Microbiotix, Inc.
    Inventors: Arnab Basu, Debra M. Mills, John D. Williams, Bing Li, Norton P. Peet, Terry L. Bowlin
  • AMPK Modulators
    Publication number: 20150266892
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
    Type: Application
    Filed: February 19, 2015
    Publication date: September 24, 2015
    Inventors: Neal C. Birnberg, Hong Liu, Qing Ping Weng, Haibo Shang, Pan Yin, Sharanappa B. Rajur, Hwa-Ok Kim, Paresh D. Salgaonkar, Norton P. Peet
  • Inhibitors of filovirus entry into host cells
    Patent number: 9101635
    Abstract: Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.
    Type: Grant
    Filed: July 10, 2010
    Date of Patent: August 11, 2015
    Assignee: MICROBIOTIX, INC.
    Inventors: Arnab Basu, Debra M. Mills, Norton P. Peet, John D. Williams
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20150158884
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: January 16, 2015
    Publication date: June 11, 2015
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • AMPK modulators
    Patent number: 8980895
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: March 17, 2015
    Assignee: Mercury Therapeutics, Inc.
    Inventors: Neal C. Birnberg, Hong Liu, Qing Ping Weng, Haibo Shang, Pan Yin, Sharanappa B. Rajur, Hwa-Ok Kim, Paresh D. Salgaonkar, Norton P. Peet
  • Histone deacetylase inhibitors
    Patent number: 8957066
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I), wherein the substituents are as defined herein.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 17, 2015
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Vincent Jacques, James R Rusche, Norton P. Peet, Jasbir Singh
  • Inhibitors of bacterial type III secretion system
    Patent number: 8906945
    Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: December 9, 2014
    Assignee: Microbiotix, Inc.
    Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams
  • INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM
    Publication number: 20140219995
    Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
    Type: Application
    Filed: July 13, 2012
    Publication date: August 7, 2014
    Applicant: MICROBIOTIX, INC.
    Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams, Matthew Torhan
  • INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM
    Publication number: 20140142134
    Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Psendomonas spp., Yersinia spp., en tero pathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
    Type: Application
    Filed: July 13, 2012
    Publication date: May 22, 2014
    Applicant: MICROBIOTIX, INC.
    Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams, Matthew Torhan
  • Histone Deacetylase Inhibitors
    Publication number: 20140051680
    Abstract: This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: February 28, 2012
    Publication date: February 20, 2014
    Applicant: REPLIGEN CORPORATION
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS
    Publication number: 20130331456
    Abstract: The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.
    Type: Application
    Filed: September 13, 2011
    Publication date: December 12, 2013
    Inventors: Arnab Basu, Debra M. Mills, John D. Williams, Bing Li, Norton P. Peet, Terry L. Bowlin
  • AMPK MODULATORS
    Publication number: 20120302576
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
    Type: Application
    Filed: August 9, 2012
    Publication date: November 29, 2012
    Inventors: Neal C. Birnberg, Hong Liu, Qing Ping Weng, Haibo Shang, Pan Yin, Sharanappa B. Rajur, Hwa-Ok Kim, Paresh D. Salgaonkar, Norton P. Peet
  • AMPK modulators
    Patent number: 8273744
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: September 25, 2012
    Assignee: Mercury Therapeutics, Inc.
    Inventors: Neal C. Birnberg, Hong Liu, Qing Ping Weng, Haibo Shang, Pan Yin, Sharanappa B. Rajur, Hwa-Ok Kim, Paresh D. Salgaonkar, Norton P. Peet
  • INHIBITORS OF FILOVIRUS ENTRY INTO HOST CELLS
    Publication number: 20120189614
    Abstract: Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.
    Type: Application
    Filed: July 10, 2010
    Publication date: July 26, 2012
    Applicant: Crobiotix, Inc.
    Inventors: Arnab Basu, Debra M. Mills, Norton P. Peet, John D. Williams
  • Inhibitors Of Bacterial Type III Secretion System
    Publication number: 20120114633
    Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.
    Type: Application
    Filed: April 6, 2010
    Publication date: May 10, 2012
    Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams
  • Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors
    Publication number: 20120094971
    Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
    Type: Application
    Filed: September 3, 2009
    Publication date: April 19, 2012
    Applicant: REPLIGEN CORPORATION
    Inventors: James R. Rusche, Norton P. Peet, Allen T. Hopper
  • INHIBITORS OF BACTERIAL BIOFILM FORMATION
    Publication number: 20110098323
    Abstract: Organic compounds are described for use in inhibiting or preventing formation of bacterial biofilms.
    Type: Application
    Filed: May 19, 2009
    Publication date: April 28, 2011
    Applicant: MICROBIOTIX, INC.
    Inventors: Timothy J. Opperman, John D. Williams, Norton P. Peet, Atiyya R. Khan, Steven M. Kwasny
  • AMPK MODULATORS
    Publication number: 20100009992
    Abstract: The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.
    Type: Application
    Filed: February 4, 2009
    Publication date: January 14, 2010
    Inventors: Neal C. Birnberg, Hong Liu, Qing Ping Weng, Haibo Shang, Pan Yin, Sharanappa B. Rajur, Hwa-Ok Kim, Paresh D. Salgaonkar, Norton P. Peet
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Patent number: 7429595
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4 -diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and —C(O)—.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: September 30, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Patent number: 6861524
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and —C(O)—.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: March 1, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright